How to buy Galectin Therapeutics stock - 11 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Galectin Therapeutics stock

Own Galectin Therapeutics stock in just a few minutes.

Galectin Therapeutics Inc is a biotechnology business based in the US. Galectin Therapeutics shares (GALT) are listed on the NASDAQ and all prices are listed in US Dollars. Galectin Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$141.2 million.

How to buy shares in Galectin Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Galectin Therapeutics. Find the stock by name or ticker symbol: GALT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Galectin Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Galectin Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Galectin Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Galectin Therapeutics share price

Use our graph to track the performance of GALT stocks over time.

Galectin Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$1.655 - USD$3.74
50-day moving average USD$2.2691
200-day moving average USD$2.4591
Wall St. target priceUSD$12
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.418

Buy Galectin Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Galectin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galectin Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -37.54%
Return on equity TTM -67.25%
Profit margin 0%
Book value $0.384
Market capitalisation USD$141.2 million

TTM: trailing 12 months

Shorting Galectin Therapeutics shares

There are currently 4.7 million Galectin Therapeutics shares held short by investors – that's known as Galectin Therapeutics's "short interest". This figure is 0.8% up from 4.6 million last month.

There are a few different ways that this level of interest in shorting Galectin Therapeutics shares can be evaluated.

Galectin Therapeutics's "short interest ratio" (SIR)

Galectin Therapeutics's "short interest ratio" (SIR) is the quantity of Galectin Therapeutics shares currently shorted divided by the average quantity of Galectin Therapeutics shares traded daily (recently around 258882.00999445). Galectin Therapeutics's SIR currently stands at 18.01. In other words for every 100,000 Galectin Therapeutics shares traded daily on the market, roughly 18010 shares are currently held short.

However Galectin Therapeutics's short interest can also be evaluated against the total number of Galectin Therapeutics shares, or, against the total number of tradable Galectin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galectin Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Galectin Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2066% of the tradable shares (for every 100,000 tradable Galectin Therapeutics shares, roughly 207 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Galectin Therapeutics.

Find out more about how you can short Galectin Therapeutics stock.

Galectin Therapeutics share dividends

We're not expecting Galectin Therapeutics to pay a dividend over the next 12 months.

Have Galectin Therapeutics's shares ever split?

Galectin Therapeutics's shares were split on a 1:6 basis on 22 March 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galectin Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Galectin Therapeutics shares which in turn could have impacted Galectin Therapeutics's share price.

Galectin Therapeutics share price volatility

Over the last 12 months, Galectin Therapeutics's shares have ranged in value from as little as $1.655 up to $3.74. A popular way to gauge a stock's volatility is its "beta".

GALT.US volatility(beta: 2.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galectin Therapeutics's is 2.0055. This would suggest that Galectin Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Galectin Therapeutics overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site